NR National Research CORP Stock: price and directors' dealings · United States · SEC (Form 4)Follow the National Research CORP stock price and the full insider trade history of the company, a publicly traded company based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, National Research CORP has logged 88 insider filings. Market capitalisation: €460.1m. The latest transaction was reported on 13 March 2026 (Attribution). Among the most active insiders: Amandla MK Trust. The full history is free.
Analyst consensus: bullish or bearish? Analysts rate National Research CORP Buy (bullish), based on 1 analysts. Average price target: US$26.00.
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 11,195 of 29,064 companies
FCF yld 3.4%
Earn yld 2.5%
EV/EBITDA 17.8x
ROE 42%
Gross mgn 62%
Net mgn 8.2%
Debt/EBITDA 2.6x
Pillars 2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ Sigma AI Analysis Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 13 March 2026
All Executives88 Thresholds0 Prospectus0 Other0
Declarations 88 total
◆ Executive Vice President · Executives · 12 Mar 2026
60,000 shares 0Common Stock SEC:0001008886-26-000076:0
▲ EVP & Chief Financial Officer · Executives · 17 Feb 2026
8,000 shares @ US$12.2703 19.7% of flow Common Stock SEC:0001008886-26-000043:0
Canonical exit: 18 May 2026 (T+90) ● EVP & Chief Financial Officer · Executives · 29 Dec 2025
21,271 shares @ US$18.66 80.3% of flow Common Stock SEC:0001008886-26-000015:0
◆ EVP, Strategic Insights · Executives · 5 Jan 2026
100,000 shares 0Common Stock SEC:0001008886-26-000012:0
◇ Chairman · Executives · 5 Jan 2026
9,145 shares @ US$15.23 26.8% of flow Common Stock SEC:0001008886-26-000008:0
◇ EVP & Chief Operating Officer · Executives · 15 Dec 2025
12,346 shares @ US$15.23 50.5% of flow Common Stock SEC:0001008886-25-000321:0
◆ EVP & Chief Financial Officer · Executives · 29 Sept 2025
172,000 shares 0Common Stock SEC:0001008886-25-000265:0
▲ Chief Accounting Officer · Executives · 31 Jul 2025
771 shares @ US$12.97 100.0% of flow Common Stock SEC:0001008886-25-000239:0
Canonical exit: 29 Oct 2025 (T+90) ◆ Chief Executive Officer · Executives · 1 Jun 2025
500,000 shares 0Common Stock SEC:0001008886-25-000176:0
2,500 shares @ US$13.5895 100.0% of flow Common Stock SEC:0001008886-25-000118:0
Canonical exit: 10 Aug 2025 (T+90) 650 shares 0Common Stock SEC:0001008886-25-000086:0
4,755,317 shares 0Common Stock SEC:0001008886-25-000088:0
4,755,317 shares 0Common Stock SEC:0001008886-25-000090:0
◆ Chief Corp. Development Off. · Executives · 7 Apr 2025
100,000 shares 0Common Stock SEC:0001008886-25-000069:0
◆ Chief Operating Officer · Executives · 7 Apr 2025
100,000 shares 0Common Stock SEC:0001008886-25-000068:0
◇ CEO & President · Executives · 2 Jan 2025
10,014 shares @ US$13.17 39.2% of flow Common Stock SEC:0001008886-25-000012:0
◇ Director · Executives · 27 Mar 2024
9,259 shares @ US$14.95 100.0% of flow Common Stock SEC:0001008886-24-000100:0
598,653 shares @ US$40.54 61.9% of flow Common Stock SEC:0001008886-24-000079:0
4,600 shares @ US$41.2211 0.4% of flow Common Stock SEC:0001008886-24-000028:0
364,625 shares @ US$41.53 38.1% of flow Common Stock SEC:0001008886-24-000026:0
180,500 shares @ US$40.2103 13.6% of flow Common Stock SEC:0001008886-24-000023:0
◇ CEO & President · Executives · 2 Jan 2024
2,904 shares @ US$18.80 15.2% of flow Common Stock SEC:0001008886-24-000024:0
21,884 shares @ US$41.5501 1.7% of flow Common Stock SEC:0001008886-23-000241:0
4,738 shares @ US$41.5641 0.4% of flow Common Stock SEC:0001008886-23-000238:0
100 shares @ US$41.60 0.0% of flow Common Stock SEC:0001008886-23-000236:0
25 of 88 declarations
Load more (63 remaining) 关于 National Research CORP National Research Corp. (NASDAQ: NRC) 以 NRC Health 品牌运营,是一家在美国上市的医疗保健分析和软件公司,专注于衡量和改善患者、消费者、员工和护理团队的体验。对于投资者而言,该公司应被视为专业的医疗保健技术提供商,而非广泛的软件供应商。其股票在美国纳斯达克市场交易,公司总部位于内布拉斯加州林肯市。([sec.gov](https://www.sec.gov/Archives/edgar/data/70487/000100888625000093/ars.pdf))
NRC 由 Michael D. Hays 于 1981 年创立,最初是一家以研究为导向的企业,现已发展成为一个围绕“人类理解”和医疗保健体验管理构建的平台业务。公司报告只有一个运营部门,收入主要来自美国。其业务模式主要基于订阅,这支持了经常性收入的可见性,尽管合同续订仍然是需要关注的重要因素。([nrchealth.com](https://nrchealth.com/wp-content/uploads/2016/10/NRC2012AnnualReport-1.pdf))
NRC 的核心解决方案堆栈分为四个主要类别:患者体验、消费者体验、员工体验和市场体验。这些产品结合了调查、数字反馈捕获、分析、基准测试、声誉管理以及为医疗保健组织提供的决策支持工具。实际上,NRC 帮助医院、卫生系统和其他提供商了解完整的护理旅程,并改善参与度、忠诚度、合规性,在某些情况下,还包括基于价值的护理框架下的报销。其竞争优势来自于其专注于医疗保健的特点、集成的体验管理平台以及在领域专业知识和可操作见解与软件功能同等重要的市场中长期建立的客户关系。([sec.gov](https://www.sec.gov/Archives/edgar/data/70487/000100888625000093/ars.pdf))
从地理上看,NRC 绝大部分业务集中在美国。公司表示,其 2024 年的收入主要来自美国,而其加拿大业务已基本清算,目前加拿大已成为非重要地理区域。公司总部仍设在内布拉斯加州林肯市,公司还在翻新其主要办公大楼,这突显了其稳定的国内运营基础。([sec.gov](https://www.sec.gov/Archives/edgar/data/70487/000100888625000093/ars.pdf))
近期发展对市场观察者很重要。2025 年 3 月,NRC 宣布 Trent Green 将于 2025 年 6 月 1 日起担任首席执行官,接替创始人 Michael Hays,后者转任董事长。公司还在 2025 年 4 月发布了 2025 年第一季度业绩,并继续强调产品创新和医疗保健合作伙伴关系的拓展。近期客户的成功获取和行业认可,包括患者体验奖项,表明 NRC 仍在积极争夺其利基市场中的战略客户。([nrchealth.com](https://nrchealth.com/blog/nrc-health-appoints-trent-green-chief-executive-officer/?utm_source=openai))